From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Radiation Medical Countermeasure Product Development

by Global Biodefense Staff
March 24, 2014

The effects of radiation on the body may appear within minutes or develop many years after exposure. Radiation injury is directly proportional to the dose absorbed by the body and radiosensitive tissues.

Depending on the dose of whole-body or partial-body exposure to external radiation, the effects can range from an increased risk of cancer years after exposure to more acute effects, including transient nausea and vomiting; hematopoietic and gastrointestinal injury, leading to immunosuppression and infection; metabolic abnormalities; hemorrhage and anemia; damage to the cardiovascular, pulmonary, and central nervous systems; and death.

To counter such threats, the National Institute of Allergy and Infectious Diseases (NIAID) is seeking to support research and development of radiation and nuclear medical countermeasures towards licensure or approval. The supported work will encompass work performed in the drug development pathway as well as the administrative foundation necessary to facilitate and coordinate these activities in partnership with NIAID.

NIAID has issued a solicitation to re-compete a contract for provision of services, facilities, expertise and capabilities for the development of radiation/nuclear medical countermeasures (MCMs) for the mitigation or treatment of acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE).

The contractor will not identify or conduct basic research on new medical countermeasures. NIAID anticipates that products selected by the government for screening, testing, and development will come from industry, academia, and government agencies. The work to be performed under this contract will be initiated by NIAID and possibly include:

  • Animal models of radiation injury;
  • MCM testing in animal models of radiation injury;
  • The spectrum of existing and planned Investigational New Drug (IND)-enabling product development support services

One Indefinite Delivery, Indefinite Quantity (ID/IQ) type contract is anticipated to be awarded to an organization to provide the comprehensive suite of product development services. The anticipated period of performance will start in or around July 2015 and continue for 5 years.

Further details are available under Solicitation Number: HHS-NIH-NAID(AI)-SBSS-14-005.

From Our Partners
Tags: Animal ModelsRadiation

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC